{
    "analysisId": "PGA-2026-00842",
    "timestamp": "2026-02-19T12:30:00Z",
    "patient": {
        "sampleId": "SAMPLE-VCF-001",
        "vcfVersion": "4.2"
    },
    "drug": "Warfarin",
    "overallRisk": "ADJUST_DOSE",
    "overallRiskLabel": "Dose Adjustment Required",
    "riskDescription": "Genomic analysis indicates significantly altered warfarin metabolism. Standard dosing carries elevated risk of adverse events. Pharmacogenomic-guided dosing is strongly recommended.",
    "confidenceScore": 0.87,
    "confidenceBreakdown": [
        {
            "factor": "Genotype Quality",
            "score": 0.92,
            "label": "High"
        },
        {
            "factor": "Variant Coverage",
            "score": 0.85,
            "label": "High"
        },
        {
            "factor": "Drug-Gene Evidence",
            "score": 0.88,
            "label": "High"
        },
        {
            "factor": "Population Data",
            "score": 0.78,
            "label": "Moderate"
        },
        {
            "factor": "Clinical Annotation",
            "score": 0.91,
            "label": "High"
        }
    ],
    "genes": [
        {
            "gene": "CYP2C9",
            "diplotype": "*1/*3",
            "phenotype": "Intermediate Metabolizer",
            "activityScore": 1.0,
            "drugRecommendation": "Reduce warfarin dose by 20-30%. Initiate at lower dose and titrate based on INR monitoring.",
            "guidelineSource": "CPIC 2017",
            "variants": [
                {
                    "rsid": "rs1057910",
                    "chromosome": "10",
                    "position": 96741053,
                    "ref": "A",
                    "alt": "C",
                    "genotype": "A/C",
                    "consequence": "missense_variant",
                    "clinicalSignificance": "Pathogenic",
                    "alleleFrequency": 0.065,
                    "qualityScore": 99,
                    "readDepth": 42
                }
            ]
        },
        {
            "gene": "VKORC1",
            "diplotype": "-1639 G>A (AG)",
            "phenotype": "Intermediate Expression",
            "activityScore": null,
            "drugRecommendation": "Warfarin sensitivity increased. Recommend starting dose 25-50% below standard.",
            "guidelineSource": "CPIC 2017",
            "variants": [
                {
                    "rsid": "rs9923231",
                    "chromosome": "16",
                    "position": 31107689,
                    "ref": "C",
                    "alt": "T",
                    "genotype": "C/T",
                    "consequence": "upstream_gene_variant",
                    "clinicalSignificance": "Drug Response",
                    "alleleFrequency": 0.39,
                    "qualityScore": 98,
                    "readDepth": 56
                }
            ]
        },
        {
            "gene": "CYP2C19",
            "diplotype": "*1/*1",
            "phenotype": "Normal Metabolizer",
            "activityScore": 2.0,
            "drugRecommendation": "No CYP2C19-based dose adjustment required for warfarin. Standard dosing applies for CYP2C19-metabolized co-medications.",
            "guidelineSource": "CPIC 2020",
            "variants": []
        }
    ],
    "explanations": [
        {
            "title": "Why is dose adjustment recommended?",
            "content": "Your CYP2C9 *1/*3 diplotype results in intermediate enzyme activity, meaning warfarin is metabolized more slowly than in normal metabolizers. Combined with the VKORC1 -1639 G>A heterozygous genotype, which increases sensitivity to warfarin, the net effect is a substantially lower dose requirement to achieve therapeutic INR."
        },
        {
            "title": "What does Intermediate Metabolizer mean?",
            "content": "Intermediate Metabolizer status for CYP2C9 indicates that one copy of the gene has reduced function. This results in slower clearance of drugs metabolized by this enzyme, including warfarin, leading to higher plasma drug levels at standard doses."
        },
        {
            "title": "How reliable is this analysis?",
            "content": "The overall confidence score of 87% reflects high genotype quality, strong drug-gene evidence from CPIC guidelines, and adequate variant coverage. The moderate population data score indicates that some frequency data may be limited for certain ancestries."
        },
        {
            "title": "What should I do next?",
            "content": "Share this report with your prescribing physician or clinical pharmacist. They can use the pharmacogenomic-guided dosing recommendations to optimize your warfarin dose. Regular INR monitoring is still essential."
        }
    ],
    "qualityMetrics": {
        "totalVariantsAnalyzed": 342,
        "clinicallyRelevantVariants": 2,
        "averageReadDepth": 38.5,
        "averageQualityScore": 95.2,
        "genotypeConcordance": 0.997,
        "vcfPassRate": 0.94
    },
    "metadata": {
        "pipelineVersion": "1.4.0",
        "referenceGenome": "GRCh38",
        "annotationSources": [
            "ClinVar 2025-12",
            "PharmGKB 2025-Q4",
            "CPIC Guidelines"
        ],
        "analysisDate": "2026-02-19T12:30:00Z"
    }
}